Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.
Passera A, Muscianisi E, Demanse D, Okoye GA, Jemec GBE, Mayo T, Hsiao J, Shi VY, Byrd AS, Wei X, Uhlmann L, Vandemeulebroecke M, Ravichandran S, Porter ML. Passera A, et al. Among authors: ravichandran s. J Eur Acad Dermatol Venereol. 2024 Aug 5. doi: 10.1111/jdv.20234. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39101698
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
Wei X, Passera A, Muscianisi E, Uhlmann L, Chen L, Moreno SG, Martin R, Vandemeulebroecke M, Keefe D, Ravichandran S, Wozniak MB. Wei X, et al. Among authors: ravichandran s. J Am Acad Dermatol. 2023 Dec;89(6):1285-1287. doi: 10.1016/j.jaad.2023.07.1035. Epub 2023 Aug 12. J Am Acad Dermatol. 2023. PMID: 37579844 Free article. No abstract available.
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: ravichandran s. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e496-e499. doi: 10.1111/jdv.19681. Epub 2023 Dec 6. J Eur Acad Dermatol Venereol. 2024. PMID: 38058224 Clinical Trial. No abstract available.
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Among authors: ravichandran s. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
Zouboulis CC, Kyrgidis A, Alavi A, Jemec GBE, Martorell A, Marzano AV, van der Zee HH, Wozniak MB, Martinez AL, Kasparek T, Bachhuber T, Ortmann CE, Lobach I, Thomas N, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: ravichandran s. J Eur Acad Dermatol Venereol. 2024 Oct 19. doi: 10.1111/jdv.20369. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39425517
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Week 104 results from the SUNSHINE and SUNRISE extension trial.
Kimball AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, Gottlieb AB, Jemec GBE, Reguiai Z, Villani AP, Alarcon I, Bansal A, Gasperoni F, Martin R, Paguet B, Uhlmann L, Zouater H, Ravichandran S, Alavi A. Kimball AB, et al. Among authors: ravichandran s. Br J Dermatol. 2024 Nov 29:ljae469. doi: 10.1093/bjd/ljae469. Online ahead of print. Br J Dermatol. 2024. PMID: 39611771
Revisiting the SUNSHINE and SUNRISE trials.
Kimball AB, Ravichandran S; SUNSHINE and SUNRISE trial teams. Kimball AB, et al. Among authors: ravichandran s. Lancet. 2024 Feb 17;403(10427):616. doi: 10.1016/S0140-6736(23)02612-0. Lancet. 2024. PMID: 38368010 No abstract available.
Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma.
Papargyriou A, Najajreh M, Cook DP, Maurer CH, Bärthel S, Messal HA, Ravichandran SK, Richter T, Knolle M, Metzler T, Shastri AR, Öllinger R, Jasper J, Schmidleitner L, Wang S, Schneeweis C, Ishikawa-Ankerhold H, Engleitner T, Mataite L, Semina M, Trabulssi H, Lange S, Ravichandra A, Schuster M, Mueller S, Peschke K, Schäfer A, Dobiasch S, Combs SE, Schmid RM, Bausch AR, Braren R, Heid I, Scheel CH, Schneider G, Zeigerer A, Luecken MD, Steiger K, Kaissis G, van Rheenen J, Theis FJ, Saur D, Rad R, Reichert M. Papargyriou A, et al. Among authors: ravichandran sk. Nat Biomed Eng. 2024 Dec 10. doi: 10.1038/s41551-024-01273-9. Online ahead of print. Nat Biomed Eng. 2024. PMID: 39658630
406 results